Level C· Early human research exploring benefitsProspective StudyEurope PMC

Engineering Adipose Tissue for Regenerative and Reparative Therapies

Patrick C.

Prospective Study on Skin Aging, published in Seminars in Plastic Surgery (2005) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Seminars in Plastic Surgery (2005)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC2884808

Abstract (original English)

ABSTRACT The correction or augmentation of soft tissue defects caused by trauma, tumor resection, congenital abnormalities, and aging presents a multitude of challenges in reconstructive surgery. Soft tissue defects run the gamut in terms of volume, from restoring the fullness of the face by removing wrinkles to restoring the breast mound after mastectomy. The limitations of current restorative and reparative techniques have served as drivers for the development of adipose tissue as an application area for tissue engineering. Tissue engineering is a multidisciplinary and maturing field that combines bioengineering, the clinical sciences, and the life sciences to repair or regrow tissues. This article discusses the inadequacies of current methods of correcting soft tissue defects and the innovative adipose tissue engineering strategies under pursuit to abrogate these limitations and improve patients’ outcomes and quality of life, and speculates rationally on the future. It does not discuss the applications and technologies involved with adipose-derived stem cells unless directly applied toward adipogenesis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research